SpyGlassPharma
ALISO VIEJO, CA · Biotechnology, Healthcare, Health Care · 40 employees
SpyGlass Pharma was Co-founded by Dr. Malik Y. Kahook, MD and Glenn Sussman. The company is focused on the development of novel treatments for chronic ophthalmic diseases based on technology originally developed in the Sue Anschutz-Rodgers Eye Center of the University of Colorado School of Medicine.
Funding history
- Funding Round — $75.0M — Jun 2025
- Series series d — $75.0M — Jun 2025
- Funding Round — $40.0M — Jul 2023
- Funding Round — $13.7M — Jan 2021
- Funding Round — $6.0M — Jun 2019
Recent signals
- Mar 09, 2026: SEC 8-K (8.01): On March 9, 2026, SpyGlass Pharma, Inc. issued a press release detailing positive top-line 12-month clinical updates from their Phase 1/2 trial of the Bimatoprost Drug Pad-IOL System. This development could have significant implications for the company's future product offerings and market position in ophthalmic devices. The updates are crucial for stakeholders and may influence investor confidence in the company's growth prospects. The press release serves to inform security holders about these important clinical trial results.
- Jan 06, 2026: SpyGlass Pharma Appoints Jean-Frédéric Viret as Chief Financial Officer
- Jun 05, 2025: Raised $75.0M
- Jun 02, 2025: Raised $75.0M in Series series d
- Mar 28, 2025: SpyGlass Pharma Appoints Chetan Pujara, Ph.D. as Chief Research & Development Officer
- Jul 11, 2023: Raised $40.0M
- Jan 05, 2021: Raised $13.7M
- Jun 05, 2019: Raised $6.0M
See plans & pricing → Track SpyGlassPharma’s funding, hiring, and signals — with verified contacts — on Fundz.